Next User Fee Cycle Should Focus On Policy Improvements, Gottlieb Says
US FDA commissioner wants to focus on new policies that will improve innovation and move beyond incremental process improvements.
You may also be interested in...
US FDA commissioner tells House committee that culture changes – and label changes – are among the actions the agency is pursuing to address the opioid crisis.
Generic representative raises concerns about errors from bulk scanning, while distributors and pharmacies feel failure to include inferencing will hinder patient access to drugs.
Trump administration says generic exclusivity provisions – which have been softened from the original bill – are unpredictable and could decrease competition; and while the White House is displeased with exclusivity, and wants higher user fees, it is not explicitly threatening a veto.